Business
Tetra Bio-Pharma Provides Update on its Commercialization Plan for its OTC DIN and NHP Product Programs
Tetra Bio-Pharma Provides Update on its Commercialization Plan for its OTC DIN and NHP Product Programs.
About this update from Tetra Bio-pharma Inc.
[{"type":"text","content":"\n     Tetra to partner with a Contract Sales Organization (CSO) for both TERPACAN™ and AWAYE™              Tetra expanding sales partnership agreements to the Middle East      OTTAWA, Jan. 20, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), today provided an update on its commercialization initiatives to bring its OTC Drug Identification Number (DIN) products and natural health products to market in 2020. Following the receipt of two OTC DINs from Health Canada last week, Tetra is now fully focused on the commercialization of these products and planned 2020 launch. The Company has selected a Contract Manufacturing Organization (CMO) that will initiate the manufacturing of both TERPACAN™ Hemorrhoids and TERPACAN™ Back and Muscle Pain in the upcoming weeks. This key step ensures test batches will be completed quickly and allow Tetra to focus on its marketing initiatives for both TERPACAN™ products.    As the next steps, Tetra is finalizing a commercial supply agreement and initiating activities to secure private reimbursement for the two TERPACAN™ products.  Both initiatives will allow Tetra to meet its anticipated commercial production needs for both OTC DIN products. Ahead of receiving both DIN’s from Health Canada last week, Tetra’s commercial team finalized the selection of a Contract Sales Organization (CSO) based on its ability to provide Tetra with the sales representatives required to effectively launch and market the DIN products in Canada. This firm was selected based on their track record and impressive performance. Tetra continues to discuss expanding its mandate to include the U.S. as soon as the products receive the National Drug Code (NDC) from the Food and Drug Administration (FDA).  Tetra will now begin to work with this CSO to initiate the activities required to sell and distribute the TERPACAN™ products.  This includes presenting the AWAYE™ and TERPACAN™ portfolios and securing listings in pharmacy banners in the upcoming months. Tetra will announce the CSO upon signing a definitive agreement. All of the above initiatives are key components to the commercial...